BioSpace News Archive

Ology Bioservices Inc., announced today it has been awarded a contract to advance development of a cocktail of anti-botulinum neurotoxin monoclonal antibodies (mAb) by the Department of Defense (DOD) through the Joint Science and Technology Office of the Defense Threat Reduction Agency (DTRA) and the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND).

Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of an additional 3,375,000 shares of common stock pursuant to the full exercise of the underwriters’ option to purchase additional shares from Leap’s previously announc

Texas nursing home chain using interventional analytics solution to identify change in resident condition and intervene early to avoid hospital readmissions

In support of Mayo Clinic’s digital health and practice transformation initiatives, the Mayo Clinic Department of Laboratory Medicine and Pathology has initiated an enterprise-wide digital pathology implementation of the Sectra digital slide review and image storage and management system to enable digita

In response to the Senate health committee’s white paper on preparing for future pandemics, AACC sent a letter to committee leadership detailing four key steps the government should take to ready the U.S. for the next outbreak.

Akouos, Inc. (“Akouos”) (Nasdaq: AKUS), a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for people worldwide who live with disabling hearing loss, today announced the pricing of its initial public offering of 12,500,000 shares of common stock at a public offering price of $17.00 per share, for gross proceeds of $212.5 million, before underwr

BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR) (OTCQB: BETRF) (FRA: NPAT) announces that it has consolidated its common shares on the basis of one new common share for ten old common shares (the “Consolidation”). As a result, the previously issued and outstanding 172,109,851 common

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced the pricing of concurrent underwritten public offerings of 7,400,000 shares of its common stock (the “Shares”) at a public offering price of $2.72 per share for gross proceeds of approximately $20.1 million,

FINTEPLA ® significantly and substantially reduced convulsive seizure frequency in patients whose seizures were not adequately controlled on other medications, as observed in two phase 3 placebo-controlled clinical trials Commercial launch planned for July 2020 Zogenix to host an investor call tomorrow, June 26, at 8:30 AM ET / 5:30 AM PT EMERYVILLE, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therap

StageZero Life Sciences, Ltd (TSX:SZLS) (“StageZero” or the “Company”) announces that it has today been issued a receipt by the Ontario Securities Commission in respect of its final prospectus dated June 22, 2020.